Currently, three JAK inhibitors have been approved for AD management: abrocitinib (JAK1 selective inhibitor), baricitinib (JAK1 and JAK2 inhibitor), and upadacitinib (selective and reversible JAK1 inhibitor) [9]. Here, JAK1 is linked to Alzheimer disease.